Fortress Biotech (FBIO) is currently trading at $2.13, with analysts maintaining a bullish price target of $15.00, suggesting a significant upside of over 600%. The optimism stems from its strong pipeline in pharmaceutical and biotechnology products, coupled with insider confidence, as the CEO recently purchased shares above the current market price. However, the stock has faced challenges, including a sharp decline over the past year, which investors should weigh against its long-term potential.